Lupin Ltd.

Financial

	Lupin	Mankind Pharma	Cipla
Operational Metrics
API Sector
US DMF Filings	155.0 .	n/a	1704.0 .
Pharmaceutical Sector
Number of ANDA's Filed in USA	447.0 .	55.0 .	273.0 .
Number of ANDA's Approved By USFDA	319.0 .	32.0 .	193.0 .
Domestic Sales Growth - YoY	6.6 %	n/a	8.9 %
R&D as a % of Total Sales	7.0 %	2.15 %	6.1 %
Financials
5 yr Average ROE	0.39 %	23.48 %	11.43 %
5yr average Equity Multiplier	1.85	1.4	1.39
5yr Average Asset Turnover Ratio	0.66	1.02	0.76
5yr Avg Net Profit Margin	0.74 %	16.52 %	10.96 %
Price to Book	5.7	11.0	4.63
P/E	42.12	53.68	31.02
5yr Avg Cash Conversion Cycle	-27.27 Days	-45.92 Days	-3.69 Days
Inventory Days	51.43 Days	60.23 Days	59.85 Days
Days Receivable	56.09 Days	19.33 Days	44.13 Days
Days Payable	155.83 Days	132.42 Days	114.64 Days
5yr Average Interest Coverage Ratio	3.33	47.23	23.71
5yr Avg ROCE	6.39 %	31.06 %	15.24 %
5yr Avg Operating Profit Margin	13.98 %	25.32 %	22.51 %
5 yr average Debt to Equity	0.43	0.07	0.13
5yr CAGR Net Profit	-6.65 %	17.25 %	12.9 %
5yr Average Return on Assets	0.23 %	16.73 %	8.36 %
Shareholdings
Promoter Holding	47.01 %	74.88 %	33.47 %
Share Pledged by Promoters	0.0	0.0	0.0
Change in Promoter Holding (3 Yrs)	0.15 %	-1.62 %	-3.26 %
Change in Mutual Fund Holding (3 Yrs)	3.77 %	6.74 %	2.19 %

Business

	Lupin	Mankind Pharma	Cipla
Product Wise Break-Up	Product Wise Break-Up Advanced Markets Formulations 45.0 India 34.0 Emerging Market 12.0 Active Pharmaceutical Ingredient (API) 9.0 NCD 1.0 USA 0 Developed Markets 0 Generic FDF 0 Custom Synthesis 0 Urology 0 Neuro/CNS 0 Pain/Analgesics 0 Gynaecology 0 Dermatology 0 Anti-Diabetic 0 Respiratory 0 VMN 0 Gastro - Intestinal 0 Cardiovascular 0 Anti-infectives 0 New ventures 0 Pharmaceuticals 0	Product Wise Break-Up Cardiovascular 14.0 Anti-Diabetic 8.0 Active Pharmaceutical Ingredient (API) 0 Respiratory 9.0 Custom Synthesis 0 New ventures 0 NCD 0 USA 0 Pharmaceuticals 0 Urology 5.0 Gastrointestinal 10.0 Developed Markets 0 Dermatology 6.0 Emerging Market 0 Neuro/CNS 3.0 Generic FDF 0 Anti-infectives 17.0 Gynaecology 7.0 Pain/Analgesics 5.0 India 0 Advanced Markets Formulations 0 VMN 10.0 Others 6.0	Product Wise Break-Up Cardiovascular 0 Anti-Diabetic 0 Active Pharmaceutical Ingredient (API) 0 Respiratory 0 Custom Synthesis 0 New ventures 4.22 NCD 0 USA 0 Pharmaceutical 95.78 Urology 0 Gastro - Intestinal 0 Developed Markets 0 Dermatology 0 Emerging Market 0 Neuro/CNS 0 Generic FDF 0 Anti-infectives 0 Gynaecology 0 Pain/Analgesics 0 India 0 Advanced Markets Formulations 0 VMN 0
Segment Break-Up	Segment Break-Up Pharmaceuticals 100.0 Research Services & Sale of IP`s 0	-	-
Therapeutic Area Wise Break-Up - Domestic	Therapeutic Area Wise Break-Up - Domestic Anti - Diabetes 21.0 Cardiac Science 21.0 Respiratory Systems 15.0 Gastro Intestinal 9.0 Anti-Infective 7.0 Gynecology 5.0 Central Nervous System (CNS) 5.0 Vitamins / Minerals / Nutrients 5.0 Pain Management 4.0 Anti-Tuberculosis 3.0 Anti-infectives 0 Urology 0 Gastro Intestinal 0 Antivirals 0 Derma 0 Pain / Analgesics 0 Neuro /CNS 0 Gynaec. 0 Vitamins 0 Antineoplast 0 Opthal/Otologicals 0 Oncology 0 Anti Diabetic 0 Others 5.0	-	Therapeutic Area Wise Break-Up - Domestic Cardiac Science 0 Vitamins / Minerals / Nutrients 0 Central Nervous System (CNS) 0 Ophthalmology 3.1 Gastro Intestinal 5.8 Anti - Diabetes 3.8 Anti-Infective 0 Gynecology 0 Respiratory Systems 0 Anti-Tuberculosis 0 Urology 4.8 Derma 2.7 Pain Management 3.5 Gynaec. 0 Antineoplast 0 Central Nervous System (CNS) 2.3 Oncology 0 Antivirals 3.1 Anti-Infective 15.3 Anti - Diabetes 0 Pain Management 0 Vitamins 0 Others 55.6
Location Wise Break-Up	Location Wise Break-Up USA 37.0 India 34.0 EMEA 10.0 Developed Markets 9.0 API 6.0 Japan 0 Nepal 0 Sri Lanka 0 Bangladesh 0 SAGA 0 Europe 0 Global API 0 Rest of the World 0 Emerging Markets 0 North America 0 Others 4.0	Location Wise Break-Up Japan 0 Emerging Markets 0 Sri Lanka 0 Bangladesh 0 Europe 0 Rest of the World 0 North America 0 Nepal 0 India 92.0 API 0 USA 0 EMEA 0 SAGA 0 Global API 0 Developed Markets 0 Others 8.0	Location Wise Break-Up Japan 0 Emerging Markets 0 Sri Lanka 0 Bangladesh 0 Europe 0 Rest of the World 11.0 North America 29.0 Nepal 0 India 44.0 API 0 USA 0 EMEA 0 SAGA 12.0 Global API 2.0 Developed Markets 0 Others 2.0
Acute vs Chronic	Acute vs Chronic Chronic 62.5 Acute 37.5	Acute vs Chronic Acute 65.0 Chronic 35.0	-

Lupin Ltd.

SIGN UP FOR FREE